Is Stem Cell Therapy FDA-Approved? A Country-by-Country Guide

"Is stem cell therapy FDA-approved?" has no single yes-or-no answer, because the honest answer depends on which product, which condition, and which country's regulator you're asking about. In the United States, FDA approval for stem cell products remains narrow — essentially cord blood-derived hematopoietic stem cell products plus one recently approved mesenchymal stromal cell (MSC) therapy for a specific pediatric condition — while the agency has spent the past decade issuing warning letters and pursuing injunctions against clinics selling unapproved products. Other countries take meaningfully different approaches: Japan and South Korea both run conditional-approval pathways that let some regenerative products reach patients faster and with less mature efficacy data than the FDA requires, while the EU/EMA centralizes review but still applies a high evidentiary bar. Understanding why this patchwork exists — differing tolerance for uncertainty, differing evidence thresholds, differing views on how "off-label" cell products should be regulated — is more useful than looking for a single global verdict.

What's Actually FDA-Approved in the United States

The FDA has been explicit and consistent on this point: as of its current regenerative medicine consumer guidance, "the only stem cell products that are FDA-approved for use in the United States consist of blood-forming stem cells (hematopoietic progenitor cells) derived from umbilical cord blood," and these are approved only for uses related to blood-forming and immune system disorders. That includes a handful of licensed cord blood products (for example, Allocord, Hemacord, Clevecord, and Ducord, along with products from several other licensed cord blood banks) used in hematopoietic stem cell transplantation for conditions such as certain blood cancers and inherited blood or metabolic disorders.

A notable and recent exception widened that list slightly: in December 2024, the FDA approved Ryoncil (remestemcel-L), an allogeneic bone marrow-derived mesenchymal stromal cell therapy, becoming — according to the manufacturer and multiple trade press reports — the first FDA-approved MSC product in the US. Its approval is narrow: it is indicated for steroid-refractory acute graft-versus-host disease (GvHD) in pediatric patients, not for orthopedic, aesthetic, anti-aging, or general "regenerative" use. No stem cell or stromal vascular fraction (SVF) product is FDA-approved for orthopedic conditions, autoimmune disease, neurological disease, or cosmetic use as of 2026, and the FDA's own consumer guidance continues to warn that "there continues to be broad marketing of unapproved products considered regenerative medicine therapies."

The FDA's Enforcement Record Against Unapproved Clinics

The gap between what's approved and what's marketed is where most of the regulatory action actually happens. The FDA has issued numerous warning letters to clinics and manufacturers selling unlicensed stem cell and exosome products, typically citing them for marketing unapproved biologics, misbranding, and violating current good manufacturing practice (CGMP) and current good tissue practice (CGTP) requirements. A representative recent example: in January 2025, the FDA sent a warning letter to Chara Biologics, Inc. of Chatsworth, California, over three products — an amniotic fluid product and two umbilical cord-derived cellular products — that were marketed for conditions including Alzheimer's disease, autism, heart disease, and multiple sclerosis without approval, and cited the company for CGMP and CGTP violations along with mislabeled expiration dates. The FDA's consumer guidance is blunt about what this means for patients: if a clinic is charging for a stem cell treatment outside of a legitimate, registered clinical trial, "you are likely being deceived and offered a product illegally," and the agency has documented adverse events from unapproved products including blindness, tumor formation, and serious infections.

Japan: A Faster, More Permissive Pathway

Japan regulates regenerative medicine through two separate laws. The Act on the Safety of Regenerative Medicine governs clinical use and research applications of cell therapies (including many that are offered at hospitals and clinics outside formal drug approval), while the Pharmaceuticals, Medical Devices and Other Therapeutic Products (PMD) Act governs actual marketing approval, administered by Japan's Pharmaceuticals and Medical Devices Agency (PMDA). The PMD Act's distinctive feature is a conditional, time-limited approval track: a regenerative medicine product can receive market authorization for up to seven years based on evidence of safety and only a plausible signal of efficacy, with the manufacturer required to collect further real-world outcome data before seeking full, standard approval. This is a materially lower efficacy bar at the point of initial approval than the FDA applies, and it means a product can be legally sold and administered in Japan well before it would clear a US approval standard.

South Korea: Conditional Approval for Rare, Serious Disease

South Korea's Ministry of Food and Drug Safety (MFDS) runs its own conditional approval mechanism for cell and gene therapies targeting serious or life-threatening diseases with unmet need. One illustrative case is Neuronata-R (lenzumestrocel), an autologous bone marrow-derived MSC therapy for amyotrophic lateral sclerosis (ALS) made by the Korean company CorestemChemon: the MFDS first granted it conditional approval in 2014, and updated that approval based on additional Phase 3 data in 2026. As with Japan's pathway, conditional approval lets patients access a product while the company continues gathering confirmatory evidence — a tradeoff between earlier access and mature proof of benefit that the FDA's standard pathway is generally not built to make.

European Union: Centralized Review, High Bar

The EU takes a stricter, more centralized approach. Stem cell and other advanced therapies are regulated as Advanced Therapy Medicinal Products (ATMPs) — a category covering gene therapies, somatic-cell therapies, and tissue-engineered products — and every ATMP must go through a single centralized procedure reviewed by the EMA's Committee for Advanced Therapies (CAT), with a marketing authorization ultimately granted (or refused) by the European Commission across all EU member states at once. Genuinely approved stem-cell-based ATMPs in Europe remain few; Holoclar, a product using cultured autologous limbal stem cells for corneal damage from severe eye burns, was the first stem cell-based medicine approved in the EU when it received a positive recommendation in late 2014. As in the US, this centralized, high-bar approval track sits alongside a much larger universe of clinics offering unproven cell treatments that have not gone through it.

Where "Stem Cell Tourism" Fills the Gap

Outside these formal pathways, a global market of clinics offers stem cell treatments for conditions and indications no major regulator has approved. A 2022 literature review in International Health (Lyons, Salgaonkar, and Flaherty) estimated that clinics marketing unproven stem cell treatments were concentrated in the United States (roughly 27% of surveyed clinics), followed by China, India, Thailand, and Mexico, and noted that patients seek these treatments out for reasons including cost, lack of access to trials, long domestic wait times, and the exhaustion of approved options. That finding is worth sitting with: "stem cell tourism" is not simply a story about patients leaving well-regulated countries for lightly regulated ones — a large share of unapproved marketing happens inside the US itself, which is precisely why FDA enforcement against domestic clinics has become such a persistent feature of the American regulatory landscape.

Why This Patchwork Exists

The differences above are not arbitrary. They reflect genuinely different institutional choices about how much uncertainty a regulator is willing to accept in exchange for faster patient access. The FDA's framework, built primarily around large randomized trials showing both safety and efficacy before approval, prioritizes confidence in benefit over speed. Japan's and South Korea's conditional pathways prioritize access for patients with serious, poorly treated conditions, betting that post-approval data collection can fill the evidence gap after the fact — a bet that doesn't always pay off, and one that has drawn criticism from parts of the international scientific community for approving products before their benefit is firmly established. The EU sits closer to the FDA's evidentiary caution but centralizes decision-making across many countries at once. And in places with weak enforcement capacity or fragmented oversight, clinics can operate with little regulatory friction at all, regardless of what that country's laws technically say on paper. None of these systems agree on how much evidence is "enough" — which is exactly why the same product can be legal in one country, conditionally legal in another, and outright fraudulent marketing in a third.

Bottom Line

If you're evaluating a stem cell treatment anywhere in the world, "is it FDA-approved" is the wrong first question unless you're specifically asking about the US and specifically about cord blood transplantation or pediatric steroid-refractory GvHD — those are the only indications with real FDA approval behind them as of 2026. The better questions are: What regulatory pathway, if any, has this specific product gone through in this specific country, for this specific condition? Is the clinical evidence from a registered, controlled trial, or from the clinic's own uncontrolled case series? And if a provider anywhere — in the US or abroad — is charging you directly for a stem cell injection outside of a registered clinical trial for a condition with no approved cell therapy, that should be treated as a red flag rather than reassurance, regardless of how official the paperwork looks.